News Releases


Sep 10, 2002

Insmed Discontinues Internal Development of INS-1 for Diabetes and Polycystic Ovary Syndrome - PCOS -

Sep 9, 2002

Insmed Announces Appointment of Mary Callan as Vice President of Corporate Development

Aug 19, 2002

Insmed Announces Appointment of Vice President of Commercial Development

Jul 29, 2002

Insmed Incorporated and Avecia Limited Announce Development and Manufacturing Agreement for SomatoKine

Jul 26, 2002

Insmed Incorporated Reports Second Quarter Results

Jul 25, 2002

Insmed Incorporated Invites You to Join Its 2nd Quarter Earnings Conference Call On: Tuesday, July 30, 2002 at 9:00 a.m. EDT

Jul 18, 2002

Insmed Presents Lead Drug Candidates At ENDO 2002, The 84th Annual Meeting of the Endocrine Society

Jul 17, 2002

Insmed Incorporated Receives Orphan Drug Designation for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome -Laron Syndrome- and Inititates Clinical Study

Jul 8, 2002

Insmed Incorporated Announces Investor Update Conference Call; Tuesday, July 9, 2002, at 9:00 a.m. ET - 8:00 a.m. CT

Jun 17, 2002

Insmed Reports Data On Insulin Sensitizing Drug At American Diabetes Associations Annual Meeting